Back to Search
Start Over
Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis.
- Source :
-
Gastroenterology Research & Practice . 12/24/2017, p1-9. 9p. - Publication Year :
- 2017
-
Abstract
- Serum α-fetoprotein- (AFP-) elevated gastric cancer is a rare tumor that has a poor prognosis due to high incidence of liver metastasis. This study sought to investigate the optimal treatment modality. A total of 319 gastric cancer patients with liver metastasis (GCLM) whose serum AFP levels were tested before treatment were enrolled in this study. They were classified as the serum AFP ≥ 20 ng/ml group (n = 74) and the AFP < 20 ng/ml group (n = 245). Median OS of the AFP < 20 ng/ml group was significantly longer than that of the AFP ≥ 20 ng/ml group (15.7m versus 10.9 m, P = 0 004). ORR of first-line chemotherapy was 43.3% and 56.1% of the two groups, respectively (P = 0 024). Of patients who received doublet regimen, ORR of the AFP ≥ 20 ng/ml group was significantly lower (38.2 versus 56.9%, P = 0 013), while in those received triplet regimens, ORR between two groups was similar (66.7% versus 66.7%, P = 0 676). Moreover, for patients of the AFP ≥ 20 ng/ml group, those who reached PR had a longer survival period (15.4m versus 9.4 m, P = 0 017), and combined with local treatment for liver metastasis also seemed to improve prognosis (19.2m versus 8.4 m, P = 0 003). In conclusion, serum AFP-elevated GCLM had a poorer prognosis. Multimodality treatment including aggressive first-line chemotherapy with triplet regimen may be needed when treating them. [ABSTRACT FROM AUTHOR]
- Subjects :
- *LIVER metastasis
*CANCER chemotherapy
*CANCER treatment
*RADIOTHERAPY
*CANCER cells
Subjects
Details
- Language :
- English
- ISSN :
- 16876121
- Database :
- Academic Search Index
- Journal :
- Gastroenterology Research & Practice
- Publication Type :
- Academic Journal
- Accession number :
- 126996379
- Full Text :
- https://doi.org/10.1155/2017/5080361